The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study

Not Applicable

• Conditions: Prostate Cancer
• Interventions: Device: Endorectal Balloon insertion

• Registration Number: NCT01842750
• Lead Sponsor: The Christie NHS Foundation Trust

Brief Summary

This study aims to test the hypothesis that insertion of an endorectal balloon into a patient receiving radical prostate radiotherapy by treatment radiographers is feasible without the patient experiencing undue discomfort. In addition this study will test the hypotheses that insertion of the rectal balloon prior to radiotherapy delivery stabilises rectal volume during radiotherapy treatment and minimises organ motion within the pelvis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-04-17
• Study First Submitted QC: 2013-04-25
• Study First Posted: 2013-04-30
• Study Start: 2013-08
• Status Verified: 2014-06
• Last Update Submitted: 2014-07-29
• Last Update Posted: 2014-07-30
• Primary Completion: 2014-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 10

Inclusion Criteria

• Age greater than or equal to 18 years
• ECOG performance status 0-2 (Patients with PS-2 as a result of comorbidity will be excluded).
• Patients with histologically confirmed diagnosis of prostate adenocarcinoma
• Patients who are going to undergo treatment with radical radiotherapy for prostate cancer.
• Patients must be able to receive and understand verbal and written information regarding the study and give written, informed consent
• Patients must be able to comply with trial requirements.

Exclusion Criteria

• Patients must not have a history of previous bowel surgery involving the rectum or anus.
• Evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator makes it undesirable for the patient to participate in the trial, as well as any other serious uncontrolled medical condition.
• Any patient with a medical or psychiatric condition that impairs their ability to give informed consent
• Pre-existing anorectal disease, e.g. Haemorrhoids, active bleeding, anal irritation, inflammatory bowel disease.
• Patients who are unable to give consent.
• Patients in clinical trials of new investigational medicinal products or treatment regimens unless there is written, prior agreement that the patient can also consent to this study, and that clinical data can also be used for this study.
• Prior pelvic radiotherapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Endorectal Balloon insertion	Endorectal Balloon insertion	A cone Beam scan will be performed prior to balloon insertion and then again with balloon in situ. The scans will be compared to see if the organs are stabilised. Questionnaires will be completed by the radiographer and the patient.

Primary Outcome Measures

Name	Time	Method
Tolerability	Patients will be assessed for 4 weeks throughout radiotherapy treatment	The primary aim is to determine whether the balloon insertion is tolerated throughout treatment. The principle outcome measure is the percentage of patients who tolerate the endorectal balloon throughout treatment.

Secondary Outcome Measures

Name	Time	Method
Acute toxicity	patients toxicity will be assessed over 4 weeks of radiotherapy	Acute toxicity according to CTCAE v. 4.0. This will record any reasons why balloon insertion is not possible for review.
Rectal wall sparing	patients reviewed across 4 weeks of radiotherapy treatment	Rectal wall sparing will be assessed by comparing the estimated dose determined from the imaging scans with the ERB in situ and not in situ against the planned dose from the radiotherapy planning scan
rectal volume	patient scans will be reviewed over 4 weeks of radiotherapy	Rectal volume stability will be determined by comparing the rectal volume for scans with the endorectal balloon(ERB)in situ to scans without the ERB in situ
Assessment of planning target volume (PTV) coverage	patients will be reviewed across a 4 week radiotherapy treatment period.	PTV coverage and an assessment of prostate shape and position between the weekly imaging scans with the balloon in situ will be compared with the position of the prostate and PTV coverage on the original planning scan with the balloon in situ

Trial Locations

Locations (1)

Christie Hospital NHS Foundation Trust; 🇬🇧 Manchester, United Kingdom